The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Vertex Pharmaceuticals ... AstraZeneca is the only big pharma company to have announced in-house CRISPR/Cas9 research, and earlier this year claimed its programmes were the most advanced in ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

David Paul Morris/Bloomberg via Getty Images Several pharmaceutical stocks ... Bristol-Myers Squibb, and Vertex Pharmaceuticals. The pharma industry has underperformed in 2024 despite several ...

Most investors are happy if a stock doubles within four or five years. Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders should be ecstatic. Its share price has skyrocketed 140% over the last ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

Vertex Pharmaceuticals Incorporated (VRTX) stock saw a modest uptick, ending the day at $485.37 which represents a slight increase of $6.72 or 1.40% from the prior close of $478.65. The stock opened ...

My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with us. We have Susie Lisa who is Senior Vice President, and Manisha Pai, ...

Former President Donald Trump shared AI-generated images of women wearing "Swifties for Trump" t-shirts to his Truth Social account on Sunday, including a satirical post that claimed Taylor Swift ...

This was the stock's second consecutive day of losses.